LYTIR

Company · EVMN

Evommune, Inc.

Nasdaq's symbol directory lists EVMN on the New York Stock Exchange as “Evommune, Inc. Common Stock”.

In the 12 months to Nov 8, 2026: insiders bought on 2 occasions ($146K); insiders sold on 3 occasions ($655K); 2 filings by holders of 5% or more; 6 company reports (Form 8-K, since May 26, 2026).

All insider filings at the SEC

Insider purchases and sales, by month (last 12 months)Insider purchases: $146K in total; Insider sales: $655K in total.Jun: Insider sales $655KJul: Insider purchases $146KDecJanFebMarAprMayJunJulAugSepOctNov
Insider purchases above the line: $146KInsider sales below: $655K
Dollar value of open-market purchases and sales reported on SEC Form 4, by the month traded. Sales include pre-arranged 10b5-1 plan sales.

Insider trades · SEC Form 4

Those inside the hall

Open-market purchases and sales only. Legs one person filed for one day are combined.

Who traded

  1. Drew Janice Suzann, Chief of Dev. Operations sold on 1 day all under a 10b5-1 plan latest Jun 22, 2026 sold $453K
  2. Pena Luis C., President & CEO sold on 1 day all under a 10b5-1 plan latest Jun 22, 2026 sold $169K
  3. Arthur S. Kirsch bought on 1 day latest Jul 7, 2026 bought $133K
  4. Patel Jeegar Pravinkumar, Chief Scientific Officer sold on 1 day all under a 10b5-1 plan latest Jun 22, 2026 sold $33K
  5. Carver Kyle, Chief Financial Officer bought on 1 day latest Jul 8, 2026 bought $13K
Every trade (5)
  1. BUYCarver Kyle, Chief Financial Officer bought Jul 8, 2026 1,000 shares filing $13K
  2. BUYArthur S. Kirsch bought Jul 7, 2026 10,000 shares filing $133K
  3. SELLDrew Janice Suzann, Chief of Dev. Operations sold Jun 22, 2026 20,000 shares 10b5-1 plan (scheduled) filing $453K
  4. SELLPena Luis C., President & CEO sold Jun 22, 2026 7,438 shares 10b5-1 plan (scheduled) filing $169K
  5. SELLPatel Jeegar Pravinkumar, Chief Scientific Officer sold Jun 22, 2026 1,488 shares 10b5-1 plan (scheduled) filing $33K

Large holders · SEC Schedules 13D and 13G

Five percent and over

Anyone who comes to hold more than 5% of a company's voting shares must tell the SEC. A Schedule 13D is filed by a holder who may seek to influence the company; a 13G by one who states it is a passive investor. An amendment updates an earlier filing, and a stake reported as 0% means the holder says it has sold all, or nearly all, of its shares. Every recent 13D and 13G

  1. T. Rowe Price Associates, Inc. filed Aug 14, 2026 Schedule 13G passive 1,940,939 shares filing 5.4%
  2. Andera Partners filed Aug 14, 2026 Schedule 13G/A passive filing 3.9%

Company reports · SEC Form 8-K

In its own words

Current reports the company filed with the SEC; most items are due within four business days of the event. Each line lists the report's items by the SEC's own titles; the filing says what happened. Reports collected since May 26, 2026; every 8-K at the SEC.

  1. Regulation FD disclosure filing Nov 5, 2026
  2. Entry into a material definitive agreement; Unregistered sales of equity securities; Regulation FD disclosure; Other events filing Nov 4, 2026
  3. Regulation FD disclosure filing Oct 1, 2026
  4. Regulation FD disclosure filing Sep 23, 2026
  5. Regulation FD disclosure filing Sep 15, 2026
  6. Regulation FD disclosure; Other events filing Sep 9, 2026

Sources: SEC EDGAR (Forms 4, 144 and 8-K) and STOCK Act periodic transaction reports. Filings can be late, amended or wrong at the source; see methodology.